



Supplemental Materials for

Incidence and Predictors of Zinc Deficiency in Stable Peritoneal Dialysis Patients

Andrew Davenport and Kwanpeemai Panorchan

Supplemental Table 1: Patients divided according to those with a lowered plasma zinc concentration and those with a normal value. There were no statistical differences between the two groups. Data presented as numbers, mean and standard deviation or median and (25-75% confidence limits) or percentages.

	Zinc level < 11 umol/l	Zinc level ≥11 umol/l
Mean age year	58±16	58±16
Male sex %	60.9	38.4
Diabetes %	25.3	33.8
Dialysis vintage months	9 (2-23)	14 (3-33)
Total weekly Kt/V _{urea}	2.52±0.96	2.50 ±1.15
Urinary creatinine clearance ml/min	6 (2-12)	4 (2-9)
Beta 2 microglobulin mg/l	28.6±17.3	24.8±10.7
Body weight kg	76.5±16.8	71.6±13.4
BMI kg/m ²	26.7±4.6	26.9±4.6
nPNA g/kg/day	0.90±0.25	0.89±0.30
Serum urea mmol/l	18.1±5.7	17.1±4.6
Serum phosphate mmol/l	1.52±0.45	1.56±0.42
Serum albumin g/l	37±4	39±4
C-reactive protein mg/l	3 (1-8)	4 (1-6)
Copper umol/l	17.0±3.6	16.8±4.7
Selenium umol/l	0.87±0.21	0.86±0.24
Total cholesterol mmol/l	5±1	5±1
LDL cholesterol mmol/l	2.4±1	2.3±0.9
PD protein loss g/day	5.81±2.69	5.13±2.51
Sevelamer use %	18.4	13.8



Supplemental Table 2: The effect of phosphate binders on serum trace elements and serum lipids. Percentage of patients co-prescribed HMG CoA3 reductase inhibitors (statins). Data presented as numbers, mean and standard deviation or median and (25-75% confidence limits) or percentages. There were no statistical differences between groups.

	No binder	Non-sevelamer	Sevelamer
Number of case	58	69	25
Zinc umol/l	11.4±3.0	10.8±2.7	11.2±2.9
Copper umol/l	17.6±4.2	16.7±3.7	16.2±4.4
Selenium mmol/l	0.87±0.20	0.87±0.26	0.83±0.18
Magnesium mmol/l	0.81±0.15	0.84±0.18	0.86±0.17
Total cholesterol mmol/l	5.0±1.0	5.0±1.0	5.0±2.0
HDL cholesterol mmol/l	1.4±0.5	1.5±0.9	1.3±0.6
LDL cholesterol mmol/l	2.3±0.9	2.5±1.0	2.1±1.1
Statins used %	35.7%	61.9%	70.8%



MULTIMED